Clinical Trial to to Compare of the Efficacy and Safety of Lipilou® 20 mg and Lipilou® 10 mg
NCT ID: NCT04511000
Last Updated: 2020-08-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
250 participants
INTERVENTIONAL
2017-10-11
2019-05-20
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Dyslipidemia in Cardiovascular Disease
NCT01029522
A Clinical Trial Study to Evaluate Efficacy and Safety of Atorvastatin in Korean Patients With Hypercholesterolemia
NCT01081548
The Efficacy and Tolerability of Two Formulations of Atorvastatin In Korean Adult With Hypercholesterolemia
NCT01285544
Bioavailability Study for New Atorvastatin Formulation
NCT00844376
Efficacy and Safety of Fenofibrate Added on to Atorvastatin Compared With Atorvastatin
NCT01956201
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Experimental group
Lipilou®(generic atorvastatin drug) 20 mg
Patients assigned to experimental group are treated with Lipilou® 20 mg
Comparator group
Lipilou®(generic atorvastatin drug) 10 mg
Patients assigned to comparator group are treated with Lipilou® 10 mg
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Lipilou®(generic atorvastatin drug) 20 mg
Patients assigned to experimental group are treated with Lipilou® 20 mg
Lipilou®(generic atorvastatin drug) 10 mg
Patients assigned to comparator group are treated with Lipilou® 10 mg
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Patients who are legally unable to participate in clinical trials or who are unable to participate in clinical trials based on investigator's decision.
19 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Chong Kun Dang Pharmaceutical
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Korea University Ansan Hospital
Ansan, , South Korea
Sejong General Hospital
Bucheon-si, , South Korea
Dong-A University Hospital
Busan, , South Korea
Inje University Ilsan Paik Hospital
Goyang, , South Korea
Myongji Hospital
Goyang, , South Korea
Seoul National University Bundang Hospital
Seongnam, , South Korea
Korea University Guro Hospital
Seoul, , South Korea
Ulsan University Hospital
Ulsan, , South Korea
Wonju Severance Christian Hospital
Wŏnju, , South Korea
Pusan National University Yangsan Hospital
Yangsan, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
124HL17003
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.